未登录

C

Chuan-Mo Lee

chang gung memorial hospital

H指数:44

被引数:7,633

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tenofovir versus Entecavir in Treatment of Chronic Hepatitis B Virus with Severe Acute Exacerbation

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-06-0128

OAAI

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

IF12

2015-05-0150

OAAI

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment

JOURNAL OF HEPATOLOGY

IF33

2014-09-01133

PREAI

Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation

JOURNAL OF HEPATOLOGY

IF33

2014-06-0154

PREAI

Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion

HEPATOLOGY INTERNATIONAL

IF6.1

2014-05-314

PREAI

Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY

IF3.8

2014-01-1032

PREAI

A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-na⟨ve and -experienced adult Taiwanese chronic hepatitis B patients

HEPATOLOGY INTERNATIONAL

IF6.1

2013-07-3116

PREAI

Role of Viral Genotypes and Hepatitis B Viral Mutants in the Risk of Hepatocellular Carcinoma Associated with Hepatitis B and C Dual Infection

IF1.8

2013-07-0210

OAAI

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up

IF15.8

2013-06-0161

PREAI

Spontaneous Clearance of Hepatitis C Virus in an Interleukin 28B Favorable Genotype Highly Prevalent Area

IF15.8

2013-05-018

OAAI

Amino Acid Substitutions in the Core Region Associate with Insulin Resistance in Chronic Hepatitis C

IF1.8

2013-02-083

OAAI

Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion

HEPATOLOGY INTERNATIONAL

IF6.1

2012-06-2211

PREAI

Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion

HEPATOLOGY INTERNATIONAL

IF6.1

2012-06-215

PREAI

Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease

IF15.8

2011-01-01269

PREAI

Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience

LIVER INTERNATIONAL

IF5.2

2010-12-0811

PREAI

Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis

HEPATOLOGY INTERNATIONAL

IF6.1

2010-10-0832

OAAI

Hepatic Steatosis with Hepatitis B Virus/Hepatitis C Virus Dual Infection

IF15.8

2010-10-014

OAAI

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

GASTROENTEROLOGY

IF25.1

2010-10-0169

OA

Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin

HEPATOLOGY INTERNATIONAL

IF6.1

2010-09-183

OAAI

Neither Diabetes Mellitus nor Overweight Is a Risk Factor for Hepatocellular Carcinoma in a Dual HBV and HCV Endemic Area: Community Cross-Sectional and Case-Control Studies (vol 105, pg 624, 2010)

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2010-06-010

PREAI